The approval was supported by data from the ongoing Phase III MajesTEC-3 study.

Johnson & Johnson’s standout trial results for its Tecvayli and Darzalex Faspro pairing in previously treated relapsed or ...

Awareness Month, which raises awareness, action, and amplifies the voices of individuals impacted by MM, a blood cancer in which abnormal plasma cells build up in the bone marrow, producing large ...

Clinical trial led by UAB researcher supports approval of new, potentially curative treatment for multiple myeloma ...

For patients facing a multiple myeloma diagnosis, the journey is often defined by a search for the next line of defense. For survivor Julie Cohen, that search led her to the front lines of medical ...

In second- or later-line setting, combination cut risk of disease progression or death by ...

The management of smoldering multiple myeloma (MM) is undergoing a significant transformation, driven by growing evidence that early intervention can meaningfully delay progression to active disease.

Teclistamab plus daratumumab and hyaluronidase-fihj is approved for relapsed or refractory MM after one prior line of therapy, including a proteasome inhibitor and immunomodulatory agent.

Multiple myeloma is a type of blood cancer that starts in your bone marrow. This is the soft, spongy tissue inside your bones that makes most of your blood cells. It includes plasma cells, which help ...

On Thursday, the U.S. Food and Drug Administration approved Johnson & Johnson‘s JNJ Tecvayli in combination with Darzalex ...

Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced that the U.S. Food and Drug ...

Multiple myeloma is a type of blood cancer caused by a buildup of abnormal plasma cells in the bone marrow. As the abnormal plasma cells accumulate, they crowd out healthy cells and cause symptoms ...